Drug Trial Radar · NCT07007637
A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa
Last checked: Nov 19, 2026Latest source record: Jun 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
835
Planned (sponsor's estimate)
Start
Jun 27, 2025
Primary completion
Jun 13, 2028
Study completion Jun 13, 2028
Sponsor
- Lead sponsor
- MoonLake Immunotherapeutics AGIndustry
- Sponsor type
- Industry
- First posted
- Jun 6, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study to evaluate the long-term safety, tolerability, and efficacy of sonelokimab in participants with moderate to severe hidradenitis suppurativa who were previously enrolled in a parental study.
Conditions
- Hidradenitis Suppurativa
Interventions
SonelokimabDrug
Sonelokimab
Primary outcomes
What the sponsor says the trial is designed to measure.
- Long-term safety and tolerability of sonelokimab: Adverse events (AEs) following treatment with sonelokimabTime frame: 2.5-3 years
- Long-term safety and tolerability of sonelokimab: Treatment emergent adverse events (TEAEs)Time frame: 2.5-3 years
- Long-term safety and tolerability of sonelokimab: Adverse events of special interest (AESIs)Time frame: 2.5-3 years
- Long-term safety and tolerability of sonelokimab: Discontinuation of sonelokimab treatment due to AEsTime frame: 2.5-3 years
- Long-term safety and tolerability of sonelokimab: Clinically significant changes in clinical laboratory parametersTime frame: 2.5-3 years
- Long-term safety and tolerability of sonelokimab: Clinically significant changes in vital signs and standard 12-lead electrocardiogramTime frame: 2.5-3 years
Locations
166 sites in 16 countries. Site status is shown where the registry gives one.
Clinical Site
Birmingham, Alabama
Clinical Site
North Little Rock, Arkansas
Clinical Site
Los Angeles, California
Clinical Site
Northridge, California
Clinical Site
Aventura, Florida
Clinical Site
Coral Gables, Florida
Clinical Site
Hialeah, Florida
Clinical Site
Hollywood, Florida
Clinical Site
Miami, Florida
Clinical Site
Miami, Florida
Clinical Site
Ocala, Florida
Clinical Site
Tampa, Florida
Clinical Site
Tampa, Florida
Clinical Site
Macon, Georgia
Clinical Site
Sandy Springs, Georgia
Clinical Site
Skokie, Illinois
Clinical Site
West Dundee, Illinois
Clinical Site
Columbus, Indiana
Clinical Site
New Albany, Indiana
Clinical Site
Plainfield, Indiana
Clinical Site
Louisville, Kentucky
Clinical Site
Murray, Kentucky
Clinical Site
Metairie, Louisiana
Clinical Site
Boston, Massachusetts
Clinical Site
Boston, Massachusetts
Clinical Site
Ann Arbor, Michigan
Clinical Site
Canton, Michigan
Clinical Site
Clarkston, Michigan
Clinical Site
Waterford, Michigan
Clinical Site
New Brighton, Minnesota
Clinical Site
Omaha, Nebraska
Clinical Site
Las Vegas, Nevada
Clinical Site
New York, New York
Clinical Site
New York, New York
Clinical Site
The Bronx, New York
Clinical Site
Fargo, North Dakota
Clinical Site
Boardman, Ohio
Clinical Site
Columbus, Ohio
Clinical Site
Dayton, Ohio
Clinical Site
Oklahoma City, Oklahoma
Showing 40 of 166 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.